Skip to main content
. 2021 Oct 27;10(10):72. doi: 10.1038/s41389-021-00361-8

Fig. 6. Schematic diagram.

Fig. 6

IDH1 mutation suppressed the TGF-β signaling pathway and E2F4 interacted with Smad3 to inhibit expression of mesenchymal markers in the proneural subtype of GBM. However, palmitoylation of Smad3 mediated by palmitoyltransferase ZDHCH19 promoted activation of the TGF-β signaling pathway and its interaction with EP300 to promote expression of mesenchymal markers in the mesenchymal subtype of GBM. GBM glioblastoma, IDH1 isocitrate dehydrogenase 1.